Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms

World J Gastrointest Endosc. 2022 May 16;14(5):267-290. doi: 10.4253/wjge.v14.i5.267.

Abstract

Gastroenteropancreatic neuroendocrine neoplasms are a heterogenous group of rare neoplasms that are increasingly being discovered, often incidentally, throughout the gastrointestinal tract with varying degrees of activity and malignant potential. Confusing nomenclature has added to the complexity of managing these lesions. The term carcinoid tumor and embryonic classification have been replaced with gastroenteropancreatic neuroendocrine neoplasm, which includes gastrointestinal neuroendocrine and pancreatic neuroendocrine neoplasms. A comprehensive multidisciplinary approach is important for clinicians to diagnose, stage and manage these lesions. While histological diagnosis is the gold standard, recent advancements in endoscopy, conventional imaging, functional imaging, and serum biomarkers complement histology for tailoring specific treatment options. In light of developing technology, our review sets out to characterize diagnostic and therapeutic advancements for managing gastroenteropancreatic neuroendocrine tumors, including innovations in radiolabeled peptide imaging, circulating biomarkers, and endoscopic treatment approaches adapted to different locations throughout the gastrointestinal system.

Keywords: Gastroenteropancreatic neuroendocrine neoplasms; Gastrointestinal; Neuroendocrine carcinoma; Neuroendocrine tumors; Pancreas; Small intestine.

Publication types

  • Review